Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Royalty Pharma plcRPRX · Entity 3100 | EVP & Chief Scientific Officer | September 28, 2022 | September 30, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Royalty Pharma plc
Report date September 28, 2022 · Filed September 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy Reddoch RPI LLC | 820,800 |
Reported balance
After 2022-09-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-09-28 · Sale · Disposed 100,000 · Balance 820,800 F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.03 to $41.57 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| LP interests in RPI US Partners 2019, LPSEC Table II · derivative / convertible security | IndirectBy Reddoch RPI LLC | 478,870 |
Reported balance
After 2022-08-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-12 · Gift · Disposed 2,400 · Balance 478,870 F2: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange. F3: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold. F4: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F5: The Reporting Person has agreed to retain and not sell 478,870 RPI US LP Interests convertible into 4,788,700 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy IRA | 25,030 |
Reported balance
Holding disclosure · report date 2022-09-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,030 |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.03 to $41.57 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.
F3: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold.
F4: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.
F5: The Reporting Person has agreed to retain and not sell 478,870 RPI US LP Interests convertible into 4,788,700 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2022 Filed Sep 30, 2022 20:23 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 100,000 | $41.23 | $4,122,670.00 |
DisclosureSEC source: 0001209191-22-051637 · doc4.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 820,800 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.03 to $41.57 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2022 Filed Sep 30, 2022 20:23 UTC | Royalty Pharma plc RPRX · Entity 3100 | GiftLP interests in RPI US Partners 2019, LP · Derivative | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-051637 · doc4.xml · derivative · entry 3 Reddoch James F. · CIK 0001814872 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 478,870 Underlying: Class A Ordinary Shares · 24,000 shares Expires not disclosed F2 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange. F3 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold. F4 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F4 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F5 · balance_after: The Reporting Person has agreed to retain and not sell 478,870 RPI US LP Interests convertible into 4,788,700 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 21:13 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 100,000 | $41.56 | $4,155,900.00 |
DisclosureSEC source: 0000899243-22-021954 · doc4.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 920,800 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.37 to $41.73 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 27, 2022 Filed May 31, 2022 21:23 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 75,000 | $41.08 | $3,081,007.50 |
DisclosureSEC source: 0001209191-22-032906 · doc4.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 1,020,800 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.97 to $41.16 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:57 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 75,000 | $40.44 | $3,033,127.50 |
DisclosureSEC source: 0001209191-22-031366 · doc4.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 1,095,800 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.35 to $40.60 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2021 Filed Dec 30, 2021 23:03 UTC | Royalty Pharma plc RPRX · Entity 3100 | GiftLP interests in RPI US Partners 2019, LP · Derivative | 5,128 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-071636 · doc4.xml · derivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 481,270 Underlying: Class A Ordinary Shares · 51,280 shares Expires not disclosed F1 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange F2 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold. F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F4 · balance_after: The Reporting Person has agreed to retain and not sell 481,270 RPI US LP Interests convertible into 4,812,700 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances. Read SEC document |
| July 26, 2021 Filed Jul 27, 2021 21:25 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 8,949 | $39.78 | $355,976.90 |
DisclosureSEC source: 0001209191-21-048313 · doc4.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 1,170,800 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.57 to $40.21 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 26, 2021 Filed Jul 27, 2021 21:23 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 8,949 | $39.78 | $355,976.90 |
DisclosureSEC source: 0001209191-21-048310 · doc4.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 1,170,800 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.57 to $40.21 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 14, 2021 Filed Jul 14, 2021 21:17 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 2 | $42.00 | $84.00 |
DisclosureSEC source: 0000899243-21-028334 · doc4.xml · nonDerivative · entry 3 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 1,179,749 Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:17 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 17,832 | $42.01 | $749,081.31 |
DisclosureSEC source: 0000899243-21-028334 · doc4.xml · nonDerivative · entry 2 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 1,179,751 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.04 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 21:17 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 100 | $42.04 | $4,204.00 |
DisclosureSEC source: 0000899243-21-028334 · doc4.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 1,197,583 Read SEC document |
| July 08, 2021 Filed Jul 8, 2021 23:37 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 40,655 | $42.05 | $1,709,380.13 |
DisclosureSEC source: 0000950103-21-010245 · dp154125_4-reddoch.xml · nonDerivative · entry 3 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 1,197,683 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.21 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 23:37 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 2,192 | $42.01 | $92,086.80 |
DisclosureSEC source: 0000950103-21-010245 · dp154125_4-reddoch.xml · nonDerivative · entry 2 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 1,238,338 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:37 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 30,270 | $42.40 | $1,283,560.00 |
DisclosureSEC source: 0000950103-21-010245 · dp154125_4-reddoch.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 1,240,530 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.82 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 00:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 50,000 | $46.43 | $2,321,540.00 |
DisclosureSEC source: 0000950103-21-008570 · dp152445_4-reddoch.xml · nonDerivative · entry 4 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 1,270,800 F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.30 to $46.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 00:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 2,210 | $47.01 | $103,896.30 |
DisclosureSEC source: 0000950103-21-008570 · dp152445_4-reddoch.xml · nonDerivative · entry 3 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 1,320,800 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.02 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Such transactions were effected pursuant to a 10b5-1 plan adopted by the reporting person on December 30, 2020. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 00:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 47,790 | $46.57 | $2,225,522.95 |
DisclosureSEC source: 0000950103-21-008570 · dp152445_4-reddoch.xml · nonDerivative · entry 2 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 1,323,010 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.99 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Such transactions were effected pursuant to a 10b5-1 plan adopted by the reporting person on December 30, 2020. Read SEC document |
| June 04, 2021 Filed Jun 9, 2021 00:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 100,000 | $44.60 | $4,459,730.00 |
DisclosureSEC source: 0000950103-21-008570 · dp152445_4-reddoch.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 1,370,800 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.14 to $45.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:50 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 50,000 | $42.13 | $2,106,560.00 |
DisclosureSEC source: 0000950103-21-008457 · dp152318_4-reddoch.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 1,470,800 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.63 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 07, 2021 Filed May 12, 2021 01:06 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 132,080 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-007078 · dp150859_4-reddoch.xml · derivative · entry 3 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 486,398 Underlying: Class A Ordinary Shares · 1,320,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F2 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value. F3 · balance_after: The Reporting Person has agreed to retain and not sell 485,118 RPI US LP Interests convertible into 4,851,180 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances. Read SEC document |
| May 07, 2021 Filed May 12, 2021 01:06 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 1,320,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-007078 · dp150859_4-reddoch.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 1,520,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 21:56 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 55,714 | $42.10 | $2,345,592.83 |
DisclosureSEC source: 0000950103-21-005663 · dp149488_4-reddoch.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 200,000 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.45 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 11:51 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 359 | $42.32 | $15,192.88 |
DisclosureSEC source: 0000950103-21-005529 · dp149383_4-reddoch.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 255,714 Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 21:25 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 43,927 | $46.32 | $2,034,518.54 |
DisclosureSEC source: 0000950103-21-004522 · dp148366_4-reddoch.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 256,073 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.025 to $47.00 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 5, 2021 00:02 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 3,510 | $47.84 | $167,925.42 |
DisclosureSEC source: 0000950103-21-003569 · dp147386_4-reddoch.xml · nonDerivative · entry 2 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 300,000 F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.54 to $48.05 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2021 Filed Mar 5, 2021 00:02 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 96,490 | $46.89 | $4,524,232.77 |
DisclosureSEC source: 0000950103-21-003569 · dp147386_4-reddoch.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 303,510 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.54 to $47.45 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 02:45 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 12,990 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-000105 · dp143911_4-reddoch.xml · derivative · entry 5 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 618,478 Underlying: Class A Ordinary Shares · 129,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F2 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F4 · balance_after: Includes RPI US LP Interests convertible into 4,851,184 Class A Ordinary Shares that are subject to an agreement by and between the reporting person and RP Management, LLC under which the reporting person has agreed to retain and not sell such interests before February 2025. This restriction is waivable under certain circumstances. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 02:45 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 27,010 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-000105 · dp143911_4-reddoch.xml · derivative · entry 4 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 2,107 Underlying: Class A Ordinary Shares · 270,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F2 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F3 · balance_after: Includes RPI US LP Interests convertible into 21,070 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 02:45 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 129,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-000105 · dp143911_4-reddoch.xml · nonDerivative · entry 2 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 400,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 02:45 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 270,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-000105 · dp143911_4-reddoch.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 270,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. Read SEC document |
| June 18, 2020 Filed Jun 23, 2020 01:56 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI International Holdings 2019, LP · Derivative | 2,503 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012151 · dp130797_4-reddoch.xml · derivative · entry 6 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 195 Underlying: Class A Ordinary Shares · 25,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F1 · kind: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F2 · kind: This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation. F7 · derivative.exercise_date: Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F7 · derivative.expiration_date: Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F8 · balance_after: Includes RPI Intl. LP Interests convertible into 1,950 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. Read SEC document |
| June 18, 2020 Filed Jun 23, 2020 01:56 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 25,030 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012151 · dp130797_4-reddoch.xml · nonDerivative · entry 1 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 25,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. F2 · kind: This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation. F1 · price: These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP ("RPI Intl. LP"). Each limited partnership interest in RPI Intl. LP ("RPI Intl. LP Interest") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, ("Holdings"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value was paid by the Reporting Person in connection with the exchange. Read SEC document |
| June 15, 2020 Filed Jun 23, 2020 01:56 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantICAI Interests · Derivative | 200,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012151 · dp130797_4-reddoch.xml · derivative · entry 5 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 200,000 Underlying: Limited Partnership interests in RPI US Partners 2019, LP · 200,000 shares Expires not disclosed F3 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F9 · derivative.exercise_date: These ICAI Interests represent a grant of up to 200,000 RPI US LP Interests. These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. F9 · derivative.expiration_date: These ICAI Interests represent a grant of up to 200,000 RPI US LP Interests. These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. F4 · derivative.underlying: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| June 15, 2020 Filed Jun 23, 2020 01:56 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantLP interests in RPI International Holdings 2019, LP · Derivative | 2,698 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012151 · dp130797_4-reddoch.xml · derivative · entry 4 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 2,698 Underlying: Class A Ordinary Shares · 26,980 shares Expires not disclosed F3 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F7 · derivative.exercise_date: Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F7 · derivative.expiration_date: Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F8 · balance_after: Includes RPI Intl. LP Interests convertible into 1,950 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. Read SEC document |
| June 15, 2020 Filed Jun 23, 2020 01:56 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantLP interests in RPI US Partners 2019, LP · Derivative | 631,468 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012151 · dp130797_4-reddoch.xml · derivative · entry 3 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 631,468 Underlying: Class A Ordinary Shares · 6,314,680 shares Expires not disclosed F3 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F4 · derivative.exercise_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F4 · derivative.expiration_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F6 · balance_after: Includes RPI US LP Interests convertible into 4,851,184 Class A Ordinary Shares that are subject to an agreement by and between the reporting person and RP Management, LLC under which the reporting person has agreed to retain and not sell such interests before February 2025. This restriction is waivable under certain circumstances. Read SEC document |
| June 15, 2020 Filed Jun 23, 2020 01:56 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantLP interests in RPI US Partners 2019, LP · Derivative | 29,117 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012151 · dp130797_4-reddoch.xml · derivative · entry 2 Reddoch James F. · CIK 0001814872 · EVP, Research & Investments 10b5-1 filing: Not disclosed Ownership: Indirect · By Reddoch RPI LLC Disclosed balance after: 29,117 Underlying: Class A Ordinary Shares · 291,170 shares Expires not disclosed F3 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F4 · derivative.exercise_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F4 · derivative.expiration_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F5 · balance_after: Includes RPI US LP Interests convertible into 21,070 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.